keyword
Keywords Recurrent Respiratory Papillom...

Recurrent Respiratory Papillomatosis

https://read.qxmd.com/read/38624230/the-role-of-hpv11-e7-in-modulating-sting-dependent-interferon-%C3%AE-response-in-recurrent-respiratory-papillomatosis
#1
JOURNAL ARTICLE
Lijuan Chen, Huiying Hu, Yufei Pan, Yuanyuan Lu, Mengyuan Zhao, Yun Zhao, Lixin Wang, Kai Liu, Zhenkun Yu
Recurrent respiratory papillomatosis (RRP) is a rare benign tumor caused mainly by the infection of the respiratory tract epithelial cells by the human papillomavirus (HPV) type 6/11. However, the specific mechanisms underlying the inhibition of the host's innate immune response by HPV remain unclear. For this purpose, we employed single-cell RNA sequencing to analyze the states of various immune cells in RRP samples post-HPV infection and utilized a cellular model of HPV infection to elucidate the mechanisms by which HPV evades the innate immune system in RRP...
April 16, 2024: Journal of Virology
https://read.qxmd.com/read/38589763/structured-literature-review-to-identify-human-papillomavirus-s-natural-history-parameters-for-dynamic-population-models-of-vaccine-impacts
#2
REVIEW
Ibrahim Diakite, Bruno Martins, Kwame Owusu-Edusei, Cody Palmer, Oscar Patterson-Lomba, Andres Gomez-Lievano, Abigail Zion, Ryan Simpson, Vincent Daniels, Elamin Elbasha
Human papillomavirus (HPV) is a common sexually transmitted virus that can cause cervical cancer and other diseases. Dynamic transmission models (DTMs) have been developed to evaluate the health and economic impacts of HPV vaccination. These models typically include many parameters, such as natural history of the disease, transmission, demographic, behavioral, and screening. To ensure the accuracy of DTM projections, it is important to parameterize them with the best available evidence. This study aimed to identify and synthesize data needed to parametrize DTMs on the natural history of HPV infection and related diseases...
April 8, 2024: Infectious Diseases and Therapy
https://read.qxmd.com/read/38574482/human-papillomavirus-genotype-distribution-patterns-in-zimbabwe-is-the-bivalent-vaccine-sufficient
#3
REVIEW
Takudzwa Marembo, Megan Burke Fitzpatrick, Racheal S Dube Mandishora
BACKGROUND: Vaccination against Human papillomavirus (HPV) is the primary preventative strategy that has been shown to reduce the burden of HPV related diseases. Zimbabwe introduced the bivalent vaccine (HPV 16/18) in the vaccination program targeting prepubescent girls in 2018. This review is an analysis of the distribution of HPV genotypes from various studies conducted in Zimbabwe to ascertain the effectiveness of the bivalent vaccine and make recommendations for future HPV vaccine choices...
April 4, 2024: Intervirology
https://read.qxmd.com/read/38559860/angiogenesis-inhibitor-drug-induced-benign-migratory-glossitis-in-a-patient-of-juvenile-onset-recurrent-respiratory-papillomatosis-under-maintenance-therapy
#4
Namita Kalra, Rishi Tyagi, Amit Khatri, Khadeeja Kulood, Puja Sabherwal
BACKGROUND: Benign migratory glossitis or geographic tongue is a chronic recurring inflammatory condition of the oral cavity. With its ephemeral characteristics, there has been reported literature showing its association with the administration of certain drugs including angiogenesis inhibitors. The antiangiogenic drugs act by selectively inhibiting the vascular endothelial growth factor (VEGF) signaling. It has been widely used as an adjunct and a maintenance agent for the treatment of various cancers...
January 2024: International Journal of Clinical Pediatric Dentistry
https://read.qxmd.com/read/38525973/systemic-bevacizumab-for-recurrent-respiratory-papillomatosis-a-single-institution-s-experience
#5
JOURNAL ARTICLE
Raymond J So, Christopher Rayle, Henry H Joo, Emily Y Huang, Tanguy Y Seiwert, Eric H Raabe, Simon R Best
OBJECTIVES: Medical therapies to limit disease recurrence are critically needed for recurrent respiratory papillomatosis (RRP). Systemic bevacizumab is emerging as an exciting adjuvant therapy toward this end, but uptake has been poor due to the lack of experience and awareness of best prescribing practices. The objective of this study was to describe a single tertiary care academic medical center's experience using systemic bevacizumab for the treatment of RRP. METHODS: A retrospective review was performed to identify patients with RRP on systemic bevacizumab...
March 25, 2024: Laryngoscope
https://read.qxmd.com/read/38525763/pulmonary-involvement-in-recurrent-respiratory-papillomatosis-a-systematic-review
#6
REVIEW
Illari Sechi, Narcisa Muresu, Biagio Di Lorenzo, Laura Saderi, Mariangela Puci, Stefano Aliberti, Ivana Maida, Michele Mondoni, Andrea Piana, Giovanni Sotgiu
Recurrent respiratory papillomatosis (RRP) is a non-malignant disease, characterized by the production of wart-like growths in the respiratory tract, affecting both young people and adults (juvenile-onset recurrent respiratory papillomatosis, JORRP, and adult-onset recurrent respiratory papillomatosis, AORRP, respectively). Infection caused by human papillomavirus (HPV) is known as the main factor involved in RRP development. Complications of RRP may rarely occur, including lung involvement and malignant transformation...
February 28, 2024: Infectious Disease Reports
https://read.qxmd.com/read/38484282/human-papilloma-virus-hpv-vaccination-is-associated-with-reduced-number-of-surgical-treatments-an-observational-study-on-recurrent-respiratory-papillomatosis-in-northern-sweden
#7
JOURNAL ARTICLE
Alexandra Schindele, Semma Al-Sabtti, Katarina Olofsson
BACKGROUND: Recurrent respiratory papillomatosis (RRP) is a wart-like lesion mainly affecting the larynx, caused by human papillomavirus (HPV) genotypes 6 and 11. The disease affects both children and adults, and there is no cure. Surgery is the current symptom-relieving treatment; however, HPV vaccination is used as an adjuvant treatment. AIMS AND OBJECTIVES: The aims were to study effects of HPV vaccination in RRP cases and to compare juvenile-onset to adult-onset disease and high treatment frequency (TF) to low TF cases...
January 2024: Acta Oto-laryngologica
https://read.qxmd.com/read/38472063/treatment-of-juvenile-recurrent-respiratory-papillomatosis-in-a-lung-transplantation-recipient-pediatric-patient
#8
Laura Gómez-Ganda, Ignacio Iglesias-Serrano, Carlos Javier Parramón-Teixidó, Laura Batlle-Masó, José Antonio Peña-Zarza, Ana Díez-Izquierdo
No abstract text is available yet for this article.
March 11, 2024: Farmacia Hospitalaria
https://read.qxmd.com/read/38440491/diode-laser-for-juvenile-recurrent-respiratory-papillomatosis-a-case-series-of-13-patients
#9
JOURNAL ARTICLE
Sara Kamil, Samer Mohsen
Juvenile recurrent respiratory papillomatosis (JRRP) is the most common benign tumor in the larynx. It is uncommon; however, it is potentially life-threatening because it compromises the respiratory tract and required several surgeries to manage recurrences. Currently, the carbon dioxide laser is the treatment of choice. There are no studies about the role of the diode laser which is easy to use and has lower usage cost. This case series presentation reported on the therapeutic effects and recurrence rate of JRRP when using Diode laser...
February 2024: Indian Journal of Otolaryngology and Head and Neck Surgery
https://read.qxmd.com/read/38440468/clinico-pathological-factors-in-malignant-transformation-of-rrp
#10
JOURNAL ARTICLE
Smile Kajal, Aanchal Kakkar, Farhat Naz, Pranay Tanwar P, Hena Khandakar, Anurag Gupta, Alok Thakar, Hitesh Verma
Various clinico-pathological factors play role in the papilloma proliferation and pathogenesis of Recurrent respiratory papillomatosis (RRP). However, it is not known if they are directly responsible for malignant transformation of these papillomas or not. We did this study to elucidate any such association. The most recent debrided tissue of RRP in 20 patients was evaluated for p16 expression, VEGF estimation (tissue expression and serum levels), and tissue HPV DNA concentration. The final histopathology results were then correlated with these pathological factors and with clinical factors like duration of illness, age of onset of symptoms, extent of disease, etc...
February 2024: Indian Journal of Otolaryngology and Head and Neck Surgery
https://read.qxmd.com/read/38436434/quantification-and-functional-studies-of-neutrophilic-cells-identifies-distinct-papilloma-phenotypes
#11
JOURNAL ARTICLE
Ke Bai, Paul E Clavijo, Yvette Robbins, Scott M Norberg, Clint T Allen
OBJECTIVES: To characterize the distribution of immune cell subsets within laryngeal papillomas and to study the function of potentially immunosuppressive neutrophilic and regulatory T cells (Tregs). METHODS: Fresh clinical papilloma specimens were collected at the time of surgery and studied with multiparameter flow cytometry. Papilloma infiltrating neutrophilic cells and Tregs were sorted and studied functionally with ex vivo T cell suppression assays. RESULTS: Flow cytometric analysis of fresh laryngeal papillomas samples from 18 adult patients with recurrent respiratory papillomatosis revealed patterns in immune constituency between patients...
March 4, 2024: Laryngoscope
https://read.qxmd.com/read/38417025/cost-effectiveness-of-nonavalent-hpv-vaccination-in-the-netherlands
#12
JOURNAL ARTICLE
Cody Palmer, Christiaan Dolk, Ugne Sabale, Wei Wang, Kunal Saxena
BACKGROUND: A bivalent human papillomavirus vaccine (2vHPV) is currently used in the Netherlands; a nonavalent vaccine (9vHPV) is also licensed. RESEARCH DESIGN AND METHODS: We compared the public health and economic benefits of 2vHPV- and 9vHPV-based vaccination strategies in the Netherlands over 100 years using a validated deterministic dynamic transmission metapopulation model. RESULTS: Compared to 2vHPV, the 9vHPV strategy averted an additional 3,245 cases of and 825 deaths from 9vHPV-strain-attributable cancers, 4,247 cases of and 190 deaths from recurrent respiratory papillomatosis (RRP), and 1,009,637 cases of anogenital warts (AGWs), with an incremental cost-effectiveness ratio (ICER) of €4,975 per quality-adjusted life year (QALY) gained...
February 28, 2024: Expert Review of Vaccines
https://read.qxmd.com/read/38401115/adjuvant-human-papillomavirus-vaccination-in-recurrent-respiratory-papilloma-patients-older-than-45
#13
JOURNAL ARTICLE
Ryan Ivancic, Taylor Freeman, Brad de Silva, Arick Forrest, Brandon Kim, Laura Matrka
OBJECTIVES: The primary objective was to examine the intersurgical interval (ISI) of recurrent respiratory papillomatosis (RRP) in patients older than 45 years before and after a Gardasil vaccination series. METHODS: We conducted a retrospective chart review of adult patients >45 years of age diagnosed with RRP from 2012 to 2022. Patients were excluded if they did not receive at least two doses of the Gardasil vaccine series or if they underwent two or fewer surgeries during the study period...
February 24, 2024: Laryngoscope
https://read.qxmd.com/read/38333687/clinical-significance-of-type-iv-vascularization-of-laryngeal-lesions-according-to-the-ni-classification
#14
JOURNAL ARTICLE
Lucia Staníková, Peter Kántor, Katarína Fedorová, Karol Zeleník, Pavel Komínek
BACKGROUND: Scattered, small, dot-like intraepithelial papillary capillary loops (IPCLs) represent type IV epithelial vascularization according to "Ni classification" and are considered to be nonmalignant. According to the European Laryngological Society classification, these loops are malignant vascular changes. This contradiction has high clinical importance; therefore, clarification of the clinical significance of type IV vascularization according to the Ni classification is needed...
2024: Frontiers in Oncology
https://read.qxmd.com/read/38332710/off-label-drugs-in-otolaryngological-practice-against-the-background-of-legal-conditions-of-polish-legislation
#15
JOURNAL ARTICLE
Renata Kopczyk, Dariusz Jurkiewicz, Marek Rogowski, Maciej Szydłowski, Małgorzata Wierzbicka
<b><br>Introduction:</b> 'Off-label drug use' refers to the administration of drugs for unapproved indications or age groups, a different dosage or other form of administration. Considering the legal issues, there clearly exists a need to implement rules that would regulate the use of pharmaceuticals outside the scope of a marketing authorisation. The brevity and diversity of Polish laws in the field of health care leads to many interpretative doubts associated with particular legal acts...
February 29, 2024: Otolaryngologia Polska
https://read.qxmd.com/read/38309731/clinical-evaluation-of-pediatric-patients-with-recurrent-respiratory-papillomatosis-a-longitudinal-study-at-a-saudi-arabian-tertiary-care-center
#16
JOURNAL ARTICLE
Nasser Almutairi, Alanoud Alshathri, Waleed Alshareef, Abdullah Sindi, Abdullah Aljasser, Ahmed Alammar
OBJECTIVES: To study the clinical evaluation of recurrent respiratory papillomatosis (RRP) patients and the factors associated with the improvement in the Derkay's score as a measure of disease severity. METHODS: A retrospective cohort that included all juvenile RRP patients who were admitted to King Abdulaziz University Hospital, Riyadh, Saudi Arabia, between September 2015 and June 2022 and underwent surgical debulking. RESULTS: A total of 16 patients were eligible to join our study...
February 2024: Saudi Medical Journal
https://read.qxmd.com/read/38193541/profiling-of-vegf-receptors-and-immune-checkpoints-in-recurrent-respiratory-papillomatosis
#17
JOURNAL ARTICLE
Brandon Lam, Jonas Miller, Yu Jui Kung, T C Wu, Chien-Fu Hung, Richard Roden, Simon R Best
OBJECTIVES: Recurrent respiratory papillomatosis (RRP) is caused by human papilloma virus (HPV) infection of the aerodigestive tract that significantly impacts quality-of-life including the ability to communicate and breathe. Treatment was traditionally limited to serial ablative procedures in the O.R. with possible local adjuvant therapy, but new systemic therapies, such as Vascular endothelial growth factor (VEGF) inhibitors, are showing significant promise. This study aims to determine whether rationale exists for combination therapeutic approaches using VEGF inhibitors and/or immune checkpoint blockade...
January 9, 2024: Laryngoscope
https://read.qxmd.com/read/38180605/systemic-bevacizumab-for-treatment-of-recurrent-respiratory-papillomatosis
#18
JOURNAL ARTICLE
Xiaoyun Zhao, Jiajia Wang, Qi Chen, Xiufa Wu, Wenjing Mao, Jingru Ma, Rui Fang, Peijie He, Chunsheng Wei
OBJECTIVES: To characterize treatment response of recurrent respiratory papillomatosis (RRP) including adult-onset RRP (AORRP) and juvenile-onset RRP (JORRP) to systemic bevacizumab (bev), and share our treatment regimen experience. METHODS: Patients were enrolled in bev treatment based on a pathologically confirmed diagnosis of squamous papilloma. According to lesion characteristics and medical history, systemic bev was used as preoperative adjuvant therapy, postoperative adjuvant therapy, or primary therapy...
January 5, 2024: European Archives of Oto-rhino-laryngology
https://read.qxmd.com/read/38123898/factors-associated-with-iatrogenic-laryngeal-injury-in-recurrent-respiratory-papillomatosis
#19
JOURNAL ARTICLE
Raymond J So, Alexander T Hillel, Kevin M Motz, Lee M Akst, Simon R Best
OBJECTIVE: To describe iatrogenic laryngeal injury and identify its risk factors in recurrent respiratory papillomatosis (RRP) patients receiving surgical care. STUDY DESIGN: Case-control. SETTING: Tertiary care academic hospital in a metropolitan area. METHODS: Charts of patients with RRP seen at our institution from January 2002 to December 2022 were reviewed. Patients were separated into 2 cohorts based upon whether they experienced any form of iatrogenic laryngeal injury-including anterior commissure synechiae, vocal cord scar, reduced vocal fold pliability, vocal fold motion impairment, and glottic and/or subglottic stenosis...
December 20, 2023: Otolaryngology—Head and Neck Surgery
https://read.qxmd.com/read/38084790/the-larynx-is-protected-from-secondary-and-vertical-papillomavirus-infection-in-immunocompetent-mice
#20
JOURNAL ARTICLE
Renee E King, Josef Rademacher, Ella T Ward-Shaw, Rong Hu, Andrea Bilger, Simon Blaine-Sauer, Megan E Spurgeon, Susan L Thibeault, Paul F Lambert
OBJECTIVE: Mouse papillomavirus MmuPV1 causes both primary and secondary infections of the larynx in immunocompromised mice. Understanding lateral and vertical transmission of papillomavirus to the larynx would benefit patients with recurrent respiratory papillomatosis (RRP). To test the hypothesis that the larynx is uniquely vulnerable to papillomavirus infection, and to further develop a mouse model of RRP, we assessed whether immunocompetent mice were vulnerable to secondary or vertical laryngeal infection with MmuPV1...
December 12, 2023: Laryngoscope
keyword
keyword
12425
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.